Advertisement

Topics

Indivior Presents Phase III data on Potential Drug for Opioid Use Disorder

09:43 EDT 23 Jun 2017 | Drug Discovery Development

Last month, Indivior submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) to seek marketing approval for RBP-6000 for the treatment of adults with moderate-to-severe opioid use disorder as part of a complete treatment plan to include counseling and psychosocial support.
Contributed Author: 
Indivior PLC

Original Article: Indivior Presents Phase III data on Potential Drug for Opioid Use Disorder

NEXT ARTICLE

More From BioPortfolio on "Indivior Presents Phase III data on Potential Drug for Opioid Use Disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...